CN118984823A - Pparg反向激动剂及其用途 - Google Patents

Pparg反向激动剂及其用途 Download PDF

Info

Publication number
CN118984823A
CN118984823A CN202380033175.XA CN202380033175A CN118984823A CN 118984823 A CN118984823 A CN 118984823A CN 202380033175 A CN202380033175 A CN 202380033175A CN 118984823 A CN118984823 A CN 118984823A
Authority
CN
China
Prior art keywords
alkyl
pharmaceutically acceptable
compound
acceptable salt
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380033175.XA
Other languages
English (en)
Chinese (zh)
Inventor
J·E·威尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flare Treatment Co
Original Assignee
Flare Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flare Treatment Co filed Critical Flare Treatment Co
Publication of CN118984823A publication Critical patent/CN118984823A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202380033175.XA 2022-03-08 2023-03-03 Pparg反向激动剂及其用途 Pending CN118984823A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263317740P 2022-03-08 2022-03-08
US63/317,740 2022-03-08
PCT/US2023/063643 WO2023172845A1 (en) 2022-03-08 2023-03-03 Pparg inverse agonists and uses thereof

Publications (1)

Publication Number Publication Date
CN118984823A true CN118984823A (zh) 2024-11-19

Family

ID=86006834

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380033175.XA Pending CN118984823A (zh) 2022-03-08 2023-03-03 Pparg反向激动剂及其用途

Country Status (7)

Country Link
US (1) US20250186425A1 (enExample)
EP (1) EP4490147A1 (enExample)
JP (1) JP2025508542A (enExample)
CN (1) CN118984823A (enExample)
AU (1) AU2023231613A1 (enExample)
CA (1) CA3254011A1 (enExample)
WO (1) WO2023172845A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3254026A1 (en) * 2022-03-08 2023-09-14 Flare Therapeutics Inc. Inverse PPARG agonists and their uses
CN122122131A (zh) * 2023-11-10 2026-05-29 北京丹擎医药科技有限公司 杂环衍生物及其组合物和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL357678A1 (en) * 2000-04-28 2004-07-26 Sankyo Company, Limited Ppargamma modulators
US20060217425A1 (en) * 2005-03-14 2006-09-28 Jack Burton Methods of treating cancer using PPAR-gamma antagonists
CZ300589B6 (cs) * 2006-09-04 2009-06-24 Univerzita Palackého Deriváty 2-fenyl-3-hydroxychinolin-4(1H)-onu a zpusob jejich prípravy a použití
CN105982884B (zh) * 2015-02-25 2019-05-24 上海中医药大学 一种补骨脂二氢黄酮甲醚及其类似物的用途
CN107661333B (zh) * 2016-07-27 2020-12-29 清华大学 化合物在治疗肺癌中的应用
CN107522657B (zh) * 2017-09-28 2020-06-26 上海中医药大学 一种具有ppar多重激动活性的化合物及其制备方法和应用
EP3498694A1 (en) * 2017-12-12 2019-06-19 Medibiofarma, S.L. New benzamide derivatives as ppar-gamma modulators
JP7853310B2 (ja) * 2021-03-02 2026-04-28 フレア・セラピューティクス・インコーポレーテッド Ｐｐａｒｇ逆アゴニストおよびその使用
JP2024529534A (ja) * 2021-08-05 2024-08-06 フレア・セラビューティクス・インコーポレーテッド Ｐｐａｒｇ逆アゴニストおよびその使用

Also Published As

Publication number Publication date
EP4490147A1 (en) 2025-01-15
WO2023172845A1 (en) 2023-09-14
US20250186425A1 (en) 2025-06-12
AU2023231613A1 (en) 2024-09-05
JP2025508542A (ja) 2025-03-26
CA3254011A1 (en) 2023-09-14

Similar Documents

Publication Publication Date Title
EP4380928B1 (en) Pparg inverse agonists and uses thereof
JP7853310B2 (ja) Ｐｐａｒｇ逆アゴニストおよびその使用
US11820747B2 (en) PPARG inverse agonists and uses thereof
AU2010219705A1 (en) Pyridine derivative
CA2871007A1 (en) Triazolone compounds as mpges-1 inhibitors
US20250186425A1 (en) Pparg inverse agonists and uses thereof
JP2025508543A (ja) Ｐｐａｒｇインバースアゴニストおよびそれらの使用
HK40118248B (en) Pparg inverse agonists and uses thereof
HK40118248A (en) Pparg inverse agonists and uses thereof
EA051641B1 (ru) Обратные агонисты pparg и их применения
WO2024138160A1 (en) Pparg inverse agonists and uses thereof
WO2024138211A1 (en) Pparg inverse agonists and uses thereof
US20240239760A1 (en) Pparg inverse agonists and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination